ESTRO meets Asia 2024 - Abstract Book

S150

Interdisciplinary – Gynaecological

ESTRO meets Asia 2024

p=0.005. The overall symptom experience related to disease based on QOL CX24 also showed significantly improvement at p=0.021 with significant improvement in body image (p=0.022) however a decrease in sexual activity was noted that reflected in increase in sexual worry symptom domain although not significant.

Conclusion:

NACT 3 weekly followed by CRT in locally advanced cervical cancer had a good response and outcomes with acceptable toxicities, without much impact on QoL and may be explored in resource constraint settings.

Keywords: NACT , CTRT cervix, Quality of life

References:

M. McCormack , D. Gallardo Rincón , G. Eminowicz , P. Diez , L. Farrelly et al., A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial Annals of Oncology 34: S2, S1276, 2023 Nunes de Arruda F, da Costa S, et al: Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial. Int J Gynecol Cancer30: 749-756, 2020

373

Digital Poster

Dosimetric predictors of radiotherapy-induced vaginal toxicity in cervical cancer patients.

Shaha Sheik Abdulla, Dillip Kumar Parida, Deepak Kumar Das, Sandip Kumar Barik, Saroj Kumar Das Majumdar

RADIATION ONCOLOGY, AIIMS- ALL INDIA INSTITUTE OF MEDICAL SCIENCES, BHUBANESWAR, India

Purpose/Objective:

Chemoradiotherapy (CRT), followed by intracavitary brachytherapy (ICBT), is the treatment modality for locally advanced cervical cancer. Despite advances in the treatment addressing local control, overall survival, rectal, bladder, and bowel toxicities, vaginal toxicity is the least explored one(1). Radiation-induced vaginal toxicity impacts a negative quality of life, in particular for pre-menopausal women as sexual dysfunction and dyspareunia (2). Though ICRU 89 recommends the recto-vaginal point as a surrogate point dose for vaginal stenosis, not providing dose information for the entire vaginal length (3). Here, we correlate the posterior inferior border of symphysis points (PIBS) point dose in the vagina representing the upper, middle, and lower vagina during ICBT with the vaginal toxicity in clinical follow-up.

Material/Methods:

30 patients diagnosed with carcinoma cervix, including stage IIB to IVA, were prospectively included in this study from July 2022 to August 2023. All of the patients received definitive Chemoradiotherapy (CRT) 50Gy in 25 fractions to the pelvis and nodal boost (node-positive patients) by Simultaneous integrated boost (SIB) 55Gy/25 fractions in Volumetric modulated arc therapy (VMAT) along with concurrent weekly Inj. Cisplatin 40mg/m 2 was followed by intracavitary brachytherapy (ICBT) central tandem and Ovoids of 7Gy per fraction of the total weekly three